Bodo Lippitz
Research Subjects
Bodo Lippitz has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
L. Mayfrank
5 shared publications- Christer Lindquist
Department of Neurosurgery, Karolinska Hospital, Stockholm, Sweden
4 shared publications Andras Kemeny
Radiosurgery, Thornbury Radiosurgery Centre, Sheffield, UK
3 shared publicationsH. Bertalanffy
Medical Faculty of Technical University Aachen
3 shared publicationsJ. M. Gilsbach
Medical Faculty of Technical University Aachen
3 shared publicationsLars Kihlström
Departments of Neurosurgery Karolinska Hospital, Stockholm, Sweden
3 shared publications
Latest Publications
- 5 March 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 97 (3) , 657-670
Long-Term Outcomes After Gamma Knife Radiosurgery Treatment of Craniopharyngiomas: A Swedish Nationwide Cohort With a Mean Follow-Up of 21 Years
BACKGROUND AND OBJECTIVES: Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort. METHODS: All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed. RESULTS: A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival. CONCLUSION: GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.
- 5 March 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 97 (3) , 657-670
Long-Term Outcomes After Gamma Knife Radiosurgery Treatment of Craniopharyngiomas: A Swedish Nationwide Cohort With a Mean Follow-Up of 21 Years
BACKGROUND AND OBJECTIVES: Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort. METHODS: All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed. RESULTS: A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival. CONCLUSION: GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.
- 1 May 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 95 (3) , e71-e78
55-Year Follow-Up of the First Adult Patient With Craniopharyngioma Treated With Gamma Knife Radiosurgery
In May 1968, Lars Leksell and Erik-Olof Backlund achieved a pioneering breakthrough by performing the first Gamma Knife radiosurgery (GKRS) on a craniopharyngioma (CP). Today, more than 50 years later, this patient remains under continuous monitoring, providing the longest documented follow-up of a GKRS-treated CP. This case report provides a complete record of the patient’s preoperative presentation, surgical assessment, GKRS, and an extensive long-term follow-up with multiple interventions. The investigation involved analysis of archived and digitalized patient records and radiological images. The patient was a 21-year-old female who presented with amenorrhea and low levels of gonadotropins. Pneumoencephalography showed a calcified 2 × 2.5 cm mass located in the suprasellar region, indicative of a CP. Subsequent stereotactic puncture confirmed a predominantly solid nature of the CP. Given the size and composition of the tumor, the surgical team opted for GKRS. Dose planning was performed manually, with coordinates determined using Leksell’s stereotactic frame. The tumor was targeted with a total dose of 50 Gy using 179 beams of 60Co. Over the subsequent 55 years, the patient underwent radiological and clinical follow-ups. Throughout this period, 4 cystic tumor recurrences occurred and were managed by stereotactic puncture and Yttrium-90 instillation radiotherapy. The solid component remained stable without repeated GKRS. The patient suffered lateral quadrant anopsia and endocrinological deficits, necessitating pharmaceutical intervention. Despite these challenges, the patient is still living an active life at age 76 years. This case stands as historic evidence of long-term safety and efficacy of GKRS for CPs.
- 1 May 2024
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 95 (3) , e71-e78
55-Year Follow-Up of the First Adult Patient With Craniopharyngioma Treated With Gamma Knife Radiosurgery
In May 1968, Lars Leksell and Erik-Olof Backlund achieved a pioneering breakthrough by performing the first Gamma Knife radiosurgery (GKRS) on a craniopharyngioma (CP). Today, more than 50 years later, this patient remains under continuous monitoring, providing the longest documented follow-up of a GKRS-treated CP. This case report provides a complete record of the patient’s preoperative presentation, surgical assessment, GKRS, and an extensive long-term follow-up with multiple interventions. The investigation involved analysis of archived and digitalized patient records and radiological images. The patient was a 21-year-old female who presented with amenorrhea and low levels of gonadotropins. Pneumoencephalography showed a calcified 2 × 2.5 cm mass located in the suprasellar region, indicative of a CP. Subsequent stereotactic puncture confirmed a predominantly solid nature of the CP. Given the size and composition of the tumor, the surgical team opted for GKRS. Dose planning was performed manually, with coordinates determined using Leksell’s stereotactic frame. The tumor was targeted with a total dose of 50 Gy using 179 beams of 60Co. Over the subsequent 55 years, the patient underwent radiological and clinical follow-ups. Throughout this period, 4 cystic tumor recurrences occurred and were managed by stereotactic puncture and Yttrium-90 instillation radiotherapy. The solid component remained stable without repeated GKRS. The patient suffered lateral quadrant anopsia and endocrinological deficits, necessitating pharmaceutical intervention. Despite these challenges, the patient is still living an active life at age 76 years. This case stands as historic evidence of long-term safety and efficacy of GKRS for CPs.
- 23 May 2023
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part A: Central European Neurosurgery
- Vol. 84 (05) , 512
Brain Fragments: Daily Notes and Reminiscences
Lars Leksell was instrumental in stereotactic radiosurgery that he invented. Not only did he create stereotactic radiosurgery conceptionally, but, with the Gamma Knife, he also developed its technical prerequisites. Leksell died in 1986. Late in his life, he wrote the book “Brain fragments” in Swedish not as a true biography but as an episodic novel of his life. Hence, the current book is not new, but the current translation is. Leksell's son Dan translated his father's memories discretely but closely. These are the memories of one of the most formative neurosurgeons of the 20th century. In impressive simplicity and modesty, the stations of his life are shaped by the craftsmanship of the surgeon and by the creativity of the inventor, and are defined by the frustration and success of the academic neurosurgeon, all, by essence, being the expression of his joy of life. His ludic drive, courage, and the aesthetic of technical perfection were Leksell's incitement, which appear today as ingenious. Leksell developed a stereotactic frame as early as 1948, invented surgical instruments, treated patients with the trigeminal neuralgia using an early form of radiosurgery in 1951, used ultrasound in neuro-traumatology in 1954, experimented with protons as early as 1958, and developed the Gamma Knife in 1967. Rather than showing “how I did it,” Leksell's book describes how life was when it happened. From neurosurgery during the Second World War to the international scientific exchange during the 1980s, a time of constant change and development comes back to life with human images of surgeons and scientists, some of them world famous, others forgotten today. Sometimes this time of substantial progress seems remote but resembles our days in many aspects. While the book was written from the perspective of physician who formed the clinical reality of neurosurgery like only few others, it reflects the life of many during this time. Leksell did not accept the paradigms of his time; he debated the ethical aspects of clinical developments including the end of life. Leksell left the clinical ivory tower when in a political motion in 1958 he suggested the general measurement and limitation of speed in traffic from a neuro-traumatological point of view. In his discussions around scientific development including academic profiling but even in many technical aspects concerning radiosurgery and stereotactic neurosurgery, the book reflects our current reality and provides a remote perspective on issues that continue to be relevant today. Like flashlights, the episodes of this book draw a picture of a courageous man who refused to accept a priori conditions without questioning them and who truly loved life. Bodo Lippitz Received: 21 June 2022 Accepted: 28 June 2022 Article published online: 23 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 23 May 2023
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part A: Central European Neurosurgery
- Vol. 84 (05) , 512
Brain Fragments: Daily Notes and Reminiscences
Lars Leksell was instrumental in stereotactic radiosurgery that he invented. Not only did he create stereotactic radiosurgery conceptionally, but, with the Gamma Knife, he also developed its technical prerequisites. Leksell died in 1986. Late in his life, he wrote the book “Brain fragments” in Swedish not as a true biography but as an episodic novel of his life. Hence, the current book is not new, but the current translation is. Leksell's son Dan translated his father's memories discretely but closely. These are the memories of one of the most formative neurosurgeons of the 20th century. In impressive simplicity and modesty, the stations of his life are shaped by the craftsmanship of the surgeon and by the creativity of the inventor, and are defined by the frustration and success of the academic neurosurgeon, all, by essence, being the expression of his joy of life. His ludic drive, courage, and the aesthetic of technical perfection were Leksell's incitement, which appear today as ingenious. Leksell developed a stereotactic frame as early as 1948, invented surgical instruments, treated patients with the trigeminal neuralgia using an early form of radiosurgery in 1951, used ultrasound in neuro-traumatology in 1954, experimented with protons as early as 1958, and developed the Gamma Knife in 1967. Rather than showing “how I did it,” Leksell's book describes how life was when it happened. From neurosurgery during the Second World War to the international scientific exchange during the 1980s, a time of constant change and development comes back to life with human images of surgeons and scientists, some of them world famous, others forgotten today. Sometimes this time of substantial progress seems remote but resembles our days in many aspects. While the book was written from the perspective of physician who formed the clinical reality of neurosurgery like only few others, it reflects the life of many during this time. Leksell did not accept the paradigms of his time; he debated the ethical aspects of clinical developments including the end of life. Leksell left the clinical ivory tower when in a political motion in 1958 he suggested the general measurement and limitation of speed in traffic from a neuro-traumatological point of view. In his discussions around scientific development including academic profiling but even in many technical aspects concerning radiosurgery and stereotactic neurosurgery, the book reflects our current reality and provides a remote perspective on issues that continue to be relevant today. Like flashlights, the episodes of this book draw a picture of a courageous man who refused to accept a priori conditions without questioning them and who truly loved life. Bodo Lippitz Received: 21 June 2022 Accepted: 28 June 2022 Article published online: 23 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
Stereotactic Radiosurgery for Benign Cavernous Sinus Meningiomas: A Multicentre Study and Review of the Literature
Cavernous sinus meningiomas (CSMs) remain a surgical challenge due to the intimate involvement of their contained nerves and blood vessels. Stereotactic radiosurgery (SRS) is a safe and effective minimally invasive alternative for the treatment of small- to medium-sized CSMs. Objective: To assess the medium- to long-term outcomes of SRS for CSMs with respect to tumour growth, prevention of further neurological deterioration and improvement of existing neurological deficits. This multicentric study included data from 15 European institutions. We performed a retrospective observational analysis of 1222 consecutive patients harbouring 1272 benign CSMs. All were treated with Gamma Knife stereotactic radiosurgery (SRS). Clinical and imaging data were retrieved from each centre and entered into a common database. All tumours with imaging follow-up of less than 24 months were excluded. Detailed results from 945 meningiomas (86%) were then analysed. Clinical neurological outcomes were available for 1042 patients (85%). Median imaging follow-up was 67 months (mean 73.4, range 24–233). Median tumour volume was 6.2 cc (+/−7), and the median marginal dose was 14 Gy (+/−3). The post-treatment tumour volume decreased in 549 (58.1%), remained stable in 336 (35.6%) and increased in only 60 lesions (6.3%), yielding a local tumour control rate of 93.7%. Only 27 (2.8%) of the 60 enlarging tumours required further treatment. Five- and ten-year actuarial progression-free survival (PFS) rates were 96.7% and 90.1%, respectively. Tumour control rates were higher for women than men (p = 0.0031), and also for solitary sporadic meningiomas (p = 0.0201). There was no statistically significant difference in outcome for imaging-defined meningiomas when compared with histologically proven WHO Grade-I meningiomas (p = 0.1212). Median clinical follow up was 61 months (mean 64, range 6–233). Permanent morbidity occurred in 5.9% of cases at last follow-up. Stereotactic radiosurgery is a safe and effective method for treating benign CSM in the medium term to long term.
Open AccessStereotactic Radiosurgery for Benign Cavernous Sinus Meningiomas: A Multicentre Study and Review of the Literature
Cavernous sinus meningiomas (CSMs) remain a surgical challenge due to the intimate involvement of their contained nerves and blood vessels. Stereotactic radiosurgery (SRS) is a safe and effective minimally invasive alternative for the treatment of small- to medium-sized CSMs. Objective: To assess the medium- to long-term outcomes of SRS for CSMs with respect to tumour growth, prevention of further neurological deterioration and improvement of existing neurological deficits. This multicentric study included data from 15 European institutions. We performed a retrospective observational analysis of 1222 consecutive patients harbouring 1272 benign CSMs. All were treated with Gamma Knife stereotactic radiosurgery (SRS). Clinical and imaging data were retrieved from each centre and entered into a common database. All tumours with imaging follow-up of less than 24 months were excluded. Detailed results from 945 meningiomas (86%) were then analysed. Clinical neurological outcomes were available for 1042 patients (85%). Median imaging follow-up was 67 months (mean 73.4, range 24–233). Median tumour volume was 6.2 cc (+/−7), and the median marginal dose was 14 Gy (+/−3). The post-treatment tumour volume decreased in 549 (58.1%), remained stable in 336 (35.6%) and increased in only 60 lesions (6.3%), yielding a local tumour control rate of 93.7%. Only 27 (2.8%) of the 60 enlarging tumours required further treatment. Five- and ten-year actuarial progression-free survival (PFS) rates were 96.7% and 90.1%, respectively. Tumour control rates were higher for women than men (p = 0.0031), and also for solitary sporadic meningiomas (p = 0.0201). There was no statistically significant difference in outcome for imaging-defined meningiomas when compared with histologically proven WHO Grade-I meningiomas (p = 0.1212). Median clinical follow up was 61 months (mean 64, range 6–233). Permanent morbidity occurred in 5.9% of cases at last follow-up. Stereotactic radiosurgery is a safe and effective method for treating benign CSM in the medium term to long term.
- Open Access
- 26 June 2020
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 162 (9) , 2183-2196
Ten-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature
Objectives: With regard to the generally slow growth of meningioma, it is essential to analyse clinical treatment results in a long-term perspective. The purpose of the present analysis is to provide clinical data after Gamma Knife radiosurgery of meningioma in a 10-year perspective together with a review of the current literature. Methods: The current study is a retrospective analysis of 86 consecutive Swedish patients with meningiomas treated using Gamma Knife radiosurgery at the Karolinska Hospital Stockholm between March 1991 and May 2001. A total of 130 tumours were treated in 115 treatment sessions. The median radiological follow-up was 10 years (1.8–16.5 years), and the median clinical follow-up was 9.4 years (2.1–17.4 years). Results: After a median follow-up period of 10 years, local tumour control was achieved in 87.8% of meningiomas (108/123 tumours). The median latency between initial treatment and local (in-field) recurrence (n = 15) was 5.8 years (1.9–11.5). Recurrences adjacent but outside the initial radiation field occurred in 15.1% of patients (13/86) at a median of 7.5 years (1.3–15.7). New meningiomas were seen in 10.5% after a median of 5.4 years (0.9–10.8). In 72% of patients, no further treatment was required, 17.4% (15/86) underwent a second Gamma Knife treatment, 4.7% (4/86) required later open surgery and 5.8% (5/86) required both secondary treatments. Eighty-six percent of patients were neurologically unchanged or improved. A significantly lower rate of local (in-field) recurrences was seen in meningiomas treated with a prescription dose of > 13.4 Gy (7.1% vs. 24%, p = 0.02). Conclusions: The current retrospective analysis provides a 10-year follow-up and comprises one of the longest available follow-up studies of radiosurgically treated meningiomas. The current series documents a persistent high local tumour control after Gamma Knife treatment, while providing an estimation of a necessary minimum dose for long-term tumour control in meningiomas. The study confirms the validity of previous short-term data in a long-term perspective.
- 26 June 2020
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 162 (9) , 2183-2196
Open AccessTen-year follow-up after Gamma Knife radiosurgery of meningioma and review of the literature
Objectives: With regard to the generally slow growth of meningioma, it is essential to analyse clinical treatment results in a long-term perspective. The purpose of the present analysis is to provide clinical data after Gamma Knife radiosurgery of meningioma in a 10-year perspective together with a review of the current literature. Methods: The current study is a retrospective analysis of 86 consecutive Swedish patients with meningiomas treated using Gamma Knife radiosurgery at the Karolinska Hospital Stockholm between March 1991 and May 2001. A total of 130 tumours were treated in 115 treatment sessions. The median radiological follow-up was 10 years (1.8–16.5 years), and the median clinical follow-up was 9.4 years (2.1–17.4 years). Results: After a median follow-up period of 10 years, local tumour control was achieved in 87.8% of meningiomas (108/123 tumours). The median latency between initial treatment and local (in-field) recurrence (n = 15) was 5.8 years (1.9–11.5). Recurrences adjacent but outside the initial radiation field occurred in 15.1% of patients (13/86) at a median of 7.5 years (1.3–15.7). New meningiomas were seen in 10.5% after a median of 5.4 years (0.9–10.8). In 72% of patients, no further treatment was required, 17.4% (15/86) underwent a second Gamma Knife treatment, 4.7% (4/86) required later open surgery and 5.8% (5/86) required both secondary treatments. Eighty-six percent of patients were neurologically unchanged or improved. A significantly lower rate of local (in-field) recurrences was seen in meningiomas treated with a prescription dose of > 13.4 Gy (7.1% vs. 24%, p = 0.02). Conclusions: The current retrospective analysis provides a 10-year follow-up and comprises one of the longest available follow-up studies of radiosurgically treated meningiomas. The current series documents a persistent high local tumour control after Gamma Knife treatment, while providing an estimation of a necessary minimum dose for long-term tumour control in meningiomas. The study confirms the validity of previous short-term data in a long-term perspective.
- Open Access
- 1 November 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 140, 116-124
A translational concept of immuno-radiobiology
- 1 November 2019
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 140, 116-124
Open AccessA translational concept of immuno-radiobiology
- 7 April 2017
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 159 (6) , 1059-1064
European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT, EGKS, and SINCH)
In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler–Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.
- 7 April 2017
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 159 (6) , 1059-1064
European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT, EGKS, and SINCH)
In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler–Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.
- Open Access
- 18 February 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (5) , e1093722
Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis
Objective: In tumor patients, IL-6 appears to be one component of a consistent cancer-associated cytokine network resulting in both a systemic immune stimulation and a microenvironment of cancer-induced immune suppression that ultimately protects the cancer cells. IL-6 has been associated with prognosis in cancer patients, but so far a systemical analysis has not been carried out. Methods: The present meta-analysis studies the relation between IL-6 serum levels and the prognosis of cancer patients in the available clinical literature of 100 articles published between 1993 and 2013 comprising 11,583 patients. Results: The IL-6 serum level was described as significantly correlating with survival in 82/101 series comprising 85.6% of patients (9917/11,583) with 23 different cancer types. A total of 64 studies dichotomized patient cohorts according to various cut-off IL-6 serum levels: in 59/64 of these series corresponding to 94.5% of the reported patients (7694/8142) significant correlations between IL-6 serum level and survival were seen. The median survival of cancer patients had been determined above various cut-off levels of serum IL-6 in 24 dichotomized studies (26 cohorts). There was a highly significant inverse correlation between median survival of the cohorts with IL-6 serum level above cut-off (1272 patients) and their corresponding IL-6 cut-off values (Spearman R -0,48 p= < 0.001) following a linear regression when both parameters were log-transformed (p < 0.001). A significant correlation between increasing serum IL-6 and tumor stage or metastases was described in 39/44 studies and 91% of published patients (4221/4636) where clinical parameters had been specified. Conclusions: Closely associated with the patient's clinical condition and independent of the cancer histology, the increased IL-6 serum level uniformly appears to correlate with survival as paraneoplastic condition in later cancer stages independent of the cancer type. Modifications of this paraneoplastic immune reaction may offer new therapeutic options in cancer.
- 18 February 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (5) , e1093722
Open AccessCytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis
Objective: In tumor patients, IL-6 appears to be one component of a consistent cancer-associated cytokine network resulting in both a systemic immune stimulation and a microenvironment of cancer-induced immune suppression that ultimately protects the cancer cells. IL-6 has been associated with prognosis in cancer patients, but so far a systemical analysis has not been carried out. Methods: The present meta-analysis studies the relation between IL-6 serum levels and the prognosis of cancer patients in the available clinical literature of 100 articles published between 1993 and 2013 comprising 11,583 patients. Results: The IL-6 serum level was described as significantly correlating with survival in 82/101 series comprising 85.6% of patients (9917/11,583) with 23 different cancer types. A total of 64 studies dichotomized patient cohorts according to various cut-off IL-6 serum levels: in 59/64 of these series corresponding to 94.5% of the reported patients (7694/8142) significant correlations between IL-6 serum level and survival were seen. The median survival of cancer patients had been determined above various cut-off levels of serum IL-6 in 24 dichotomized studies (26 cohorts). There was a highly significant inverse correlation between median survival of the cohorts with IL-6 serum level above cut-off (1272 patients) and their corresponding IL-6 cut-off values (Spearman R -0,48 p= < 0.001) following a linear regression when both parameters were log-transformed (p < 0.001). A significant correlation between increasing serum IL-6 and tumor stage or metastases was described in 39/44 studies and 91% of published patients (4221/4636) where clinical parameters had been specified. Conclusions: Closely associated with the patient's clinical condition and independent of the cancer histology, the increased IL-6 serum level uniformly appears to correlate with survival as paraneoplastic condition in later cancer stages independent of the cancer type. Modifications of this paraneoplastic immune reaction may offer new therapeutic options in cancer.
- 1 December 2014
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 121 (Suppl_2) , 2-15
Standardization of terminology in stereotactic radiosurgery: Report from the Standardization Committee of the International Leksell Gamma Knife Society
Object: This report has been prepared to ensure more uniform reporting of Gamma Knife radiosurgery treatment parameters by identifying areas of controversy, confusion, or imprecision in terminology and recommending standards.Methods: Several working group discussions supplemented by clarification via email allowed the elaboration of a series of provisional recommendations. These were also discussed in open session at the 16th International Leksell Gamma Knife Society Meeting in Sydney, Australia, in March 2012 and approved subject to certain revisions and the performance of an Internet vote for approval from the whole Society. This ballot was undertaken in September 2012.Results: The recommendations in relation to volumes are that Gross Target Volume (GTV) should replace Target Volume (TV); Prescription Isodose Volume (PIV) should generally be used; the term Treated Target Volume (TTV) should replace TVPIV, GTV in PIV, and so forth; and the Volume of Accepted Tolerance Dose (VATD) should be used in place of irradiated volume. For dose prescription and measurement, the prescription dose should be supplemented by the Absorbed Dose, or DV% (for example, D95%), the maximum and minimum dose should be related to a specific tissue volume (for example, D2% or preferably D1 mm3), and the median dose (D50%) should be recorded routinely. The Integral Dose becomes the Total Absorbed Energy (TAE). In the assessment of planning quality, the use of the Target Coverage Ratio (TTV/ GTV), Paddick Conformity Index (PCI = TTV2/[GTV · PIV]), New Conformity Index (NCI = [GTV · PIV]/TTV2), Selectivity Index (TTV/PIV), Homogeneity Index (HI = [D2% –D98%]/D50%), and Gradient Index (GI = PIV0.5/PIV) are reemphasized. In relation to the dose to Organs at Risk (OARs), the emphasis is on dose volume recording of the VATD or the dose/volume limit (for example, V10) in most cases, with the additional use of a Maximum Dose to a small volume (such as 1 mm3) and/or a Point Dose and Mean Point Dose in certain circumstances, particularly when referring to serial organs. The recommendations were accepted by the International Leksell Gamma Knife Society by a vote of 92% to 8%.Conclusions: An agreed-upon and uniform terminology and subsequent standardization of certain methods and procedures will advance the clinical science of stereotactic radiosurgery.
- 1 December 2014
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 121 (Suppl_2) , 2-15
Standardization of terminology in stereotactic radiosurgery: Report from the Standardization Committee of the International Leksell Gamma Knife Society
Object: This report has been prepared to ensure more uniform reporting of Gamma Knife radiosurgery treatment parameters by identifying areas of controversy, confusion, or imprecision in terminology and recommending standards.Methods: Several working group discussions supplemented by clarification via email allowed the elaboration of a series of provisional recommendations. These were also discussed in open session at the 16th International Leksell Gamma Knife Society Meeting in Sydney, Australia, in March 2012 and approved subject to certain revisions and the performance of an Internet vote for approval from the whole Society. This ballot was undertaken in September 2012.Results: The recommendations in relation to volumes are that Gross Target Volume (GTV) should replace Target Volume (TV); Prescription Isodose Volume (PIV) should generally be used; the term Treated Target Volume (TTV) should replace TVPIV, GTV in PIV, and so forth; and the Volume of Accepted Tolerance Dose (VATD) should be used in place of irradiated volume. For dose prescription and measurement, the prescription dose should be supplemented by the Absorbed Dose, or DV% (for example, D95%), the maximum and minimum dose should be related to a specific tissue volume (for example, D2% or preferably D1 mm3), and the median dose (D50%) should be recorded routinely. The Integral Dose becomes the Total Absorbed Energy (TAE). In the assessment of planning quality, the use of the Target Coverage Ratio (TTV/ GTV), Paddick Conformity Index (PCI = TTV2/[GTV · PIV]), New Conformity Index (NCI = [GTV · PIV]/TTV2), Selectivity Index (TTV/PIV), Homogeneity Index (HI = [D2% –D98%]/D50%), and Gradient Index (GI = PIV0.5/PIV) are reemphasized. In relation to the dose to Organs at Risk (OARs), the emphasis is on dose volume recording of the VATD or the dose/volume limit (for example, V10) in most cases, with the additional use of a Maximum Dose to a small volume (such as 1 mm3) and/or a Point Dose and Mean Point Dose in certain circumstances, particularly when referring to serial organs. The recommendations were accepted by the International Leksell Gamma Knife Society by a vote of 92% to 8%.Conclusions: An agreed-upon and uniform terminology and subsequent standardization of certain methods and procedures will advance the clinical science of stereotactic radiosurgery.
- 1 November 2014
- Published by Elsevier in World Neurosurgery
- Vol. 82 (5) , e623-e632
Increased Survival Using Delayed Gamma Knife Radiosurgery for Recurrent High-Grade Glioma: A Feasibility Study
- 1 November 2014
- Published by Elsevier in World Neurosurgery
- Vol. 82 (5) , e623-e632
Increased Survival Using Delayed Gamma Knife Radiosurgery for Recurrent High-Grade Glioma: A Feasibility Study